abstract: Objectives. Louisiana has a high rate of @entity1047 , an easily identifiable and treatable @entity2953 . @entity1 with @entity102 , such as @entity3458 ( @entity3458 ) often forgo routine primary care visits. We hypothesized that @entity1 with @entity3458 have an increased percentage of asymptomatic @entity1047 compared with a matched population. Methods. A retrospective cohort study was performed over a 12-month period on eligible @entity1 with @entity3458 (ages 15-30 years). @entity1 were screened for asymptomatic @entity1047 by urine polymerase chain reaction during comprehensive care visits in the @entity3458 clinic. Results. Thirty-four @entity1 underwent testing during the study period, and 4/34 @entity1 (11.8%) tested positive for @entity1047 . State data show a rate of 1791/100 000 (1.8%) among a demographically matched cohort. Conclusions. @entity1 with @entity3458 had a larger percentage of asymptomatic @entity1047 than a demographically matched control population. @entity1 with @entity3458 should be screened by specialists for @entity1047 in addition to undergoing routine primary care evaluations.

title: When Is the Optimal Time to Screen for XXXX in Adolescents and Young Adults With @entity3458 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2953 :: ('MESH:D012749', 'Disease') :: ['sexually transmitted disease']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'sickle cell disease']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

entities_list: @entity1047 :: ('MESH:D002690', 'Disease') :: ['chlamydia']

answer: @entity1047 :: (MESH:D002690,Disease) :: ['Chlamydia']


abstract: UNASSIGNED: @entity36689 is an active compound in the traditional Chinese medicine Chan Su, which has been shown to induce apoptosis in a range of @entity5 cell types. However, certain @entity356 cells are known to be resistant to @entity36689 . Intracellular secreted protein acidic and rich in @entity462 ( @entity9618 ) regulates proliferation and apoptosis. This study aimed to evaluate the role of @entity9618 in @entity36689  -induced apoptosis in SGC7901 and MGC803 @entity356 cells. SGC7901 cells with high @entity9618 expression were more resistant to @entity36689 than MGC803 cells with low @entity9618 expression. This resistance was significantly reversed by small interfering (si)RNA  -mediated knockdown of @entity9618 . Furthermore, it was shown that @entity9618 negatively regulated @entity36689  -induced intrinsic apoptosis by protecting mitochondrial integrity, decreasing the release of cytoplasmic @entity4674 and increasing the ratio of @entity588 / @entity589 . In addition, @entity9618 overcame @entity36689  -induced G2/M phase arrest by increasing levels of @entity8189 and @entity7596 protein expression. @entity9618 also activated cellular survival signals, including @entity7242 and @entity584 , but not extracellular signal  -regulated kinase. This study demonstrated that @entity9618 antagonizes @entity36689  -induced apoptosis via inhibition of the intrinsic apoptosis pathway, inhibition of cell cycle arrest and activation of certain pathways involved in proliferation. This provides novel evidence for @entity9618 as a potential target by which to sensitize @entity356 cells to @entity36689 .

title: Secreted protein acidic and rich in @entity462 antagonizes XXXX  -induced apoptosis in @entity356 cells.

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity36689 :: ('MESH:C022777', 'Chemical') :: ['Bufalin', 'bufalin']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity36689 :: (MESH:C022777,Chemical) :: ['bufalin']


abstract: We investigated the effects of @entity692 (HA) coating on the purchase of pedicle screws. A total of 23 consecutive @entity1 undergoing lumbar fusion was randomly assigned to one of three treatment groups. The first received uncoated stainless-steel screws, the second screws which were partly coated with HA, and the third screws which were fully coated. The insertion torque was recorded. After 11 to 16 months, 21 screws had been extracted. The extraction torque was recorded. Radiographs were taken to assess fusion and to detect loosening of the screws. At removal, the extraction torques exceeded the upper limit of the torque wrench (600 @entity15682 ) for many HA-coated screws. The calculated mean extraction torque was 29 +/- 36 @entity15682 for the uncoated group, 447 +/- 114 @entity15682 for the partly-coated group and 574 +/- 52 @entity15682 for the fully-coated group. There were significant differences between all three groups (p < 0.001). There were more radiolucent zones surrounding the uncoated screws than the HA-coated screws (p < 0.001). HA coating of pedicle screws resulted in improved fixation with reduced risk of loosening of the screws.

title: XXXX coating improves fixation of pedicle screws. A clinical study.

entities_list: @entity692 :: ('MESH:D017886', 'Chemical') :: ['hydroxyapatite']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity692 :: (MESH:D017886,Chemical) :: ['Hydroxyapatite']


abstract: The @entity65917 gene plays an important role in the innate immunity of the @entity291 mammary gland. Associations between single nucleotide polymorphisms (SNP) CXCR1 @entity65918 and @entity65919 and udder health have been identified before in small populations. A fluorescent multiprobe PCR assay was designed specifically and validated to genotype both SNP simultaneously in a reliable and cost-effective manner. In total, 3,106 @entity291 from 50 commercial Flemish dairy herds were genotyped using this assay. Associations between genotype and detailed phenotypic data, including pathogen-specific incidence rate of clinical @entity1271 (IRCM), test-day somatic cell count, and test-day milk yield (MY) were analyzed. @entity794 IRCM tended to associate with SNP @entity65918 . @entity291 with genotype c.735GG had lower Staph. aureus IRCM compared with @entity291 with genotype c.735CC (rate ratio = 0.35, 95% confidence interval = 0.14-0.90). Additionally, a parity-specific association between Staph. aureus IRCM and SNP @entity65919 was detected. Heifers with genotype c.980GG had a lower Staph. aureus IRCM compared with heifers with genotype c.980AG (rate ratio = 0.15, 95% confidence interval = 0.04-0.56). Differences were less pronounced in multiparous @entity291 . Associations between @entity65917 genotype and somatic cell count were not detected. However, MY was associated with SNP @entity65918 . @entity291 with genotype c.735GG out-produced @entity291 with genotype c.735CC by 0.8 kg of milk/d. Results provide a basis for further research on the relation between @entity65917 polymorphism and pathogen-specific @entity1271 resistance and MY.

title: Associations between XXXX polymorphisms and pathogen-specific incidence rate of clinical @entity1271 , test-day somatic cell count, and test-day milk yield.

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

answer: @entity65917 :: (281863(Tax:9913),Gene) :: ['CXCR1']


abstract: OBJECTIVES: To evaluate our clinical experience with percutaneous image-guided radiofrequency ablation (RFA) of 200 @entity703 in a large tertiary referral university institution. @entity1 AND METHODS: Image-guided RFA (ultrasonography or computed tomography [CT]) of 200 @entity703 in 165 @entity1 from June 2004 to 2012 was prospectively evaluated. Institutional Review Board approval was granted. The treatment response and technical success were defined by absence of contrast enhancement within the @entity5 on contrast enhanced CT or magnetic resonance imaging. Both major and minor complications, glomerular filtration rate (GFR) before and after RFA, the management and outcomes of the complications, as well as oncological outcome were prospectively documented. Multivariate analysis was used to determine variables associated with major complications and also the percentage GFR change after RFA. The overall (OS), 5-year cancer-specific (CSS), local recurrence-free (LRFS) and @entity3 ( @entity3 ) rates are presented using the Kaplan-Meier curves. RESULTS: In all, 200 @entity5 were @entity6470 ablated with a mean (range) @entity5 size of 2.9 (1-5.6) cm and the mean (range) @entity1 age was 67.7 (21-88.6) years with a mean follow-up period of 46.1 months. The primary technical and overall technical success rate was 95.5% and 98.5%, respectively. Two independent predictors of successful RFA in a single sitting were @entity5 size (<3   cm) and exophytic location in multivariate logistic regression analysis. Major complications included @entity1901 (six @entity1 ), calyceal-cutaneous @entity292 (one), @entity4295 (one) and abscess (two). Two independent predictors of @entity1901 were central location and lower pole position. Within this cohort of @entity1 , only four @entity1 developed significant renal function deterioration i.e. >25% decreased in GFR. In all, 161 (98%) @entity1 of the 165 @entity1 have preservation of renal function. Any change in renal function after RFA was not influenced by @entity5 factors or solitary kidney status. In our clinical series, this yielded a 5-year OS, CSS, LRFS and @entity3 rates of 75.8%, 97.9%, 93.5% and 87.7% respectively. CONCLUSIONS: Image-guided RFA is a safe, nephron sparing and effective treatment for @entity1358 ( @entity1358 ) @entity5 with a low rate of recurrence and has good 5-year CSS and @entity3 rates.

title: Radiofrequency ablation (RFA) of XXXX ( @entity1358 ): experience in 200 @entity5 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1901 :: ('MESH:D014515', 'Disease') :: ['ureteric injury']

entities_list: @entity4295 :: ('MESH:D007683', 'Disease') :: ['acute tubular necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['RCC', 'small renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['MFS', 'metastasis-free survival']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumours']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']


abstract: BACKGROUND: Board certification is often used as a surrogate indicator of provider competence, although few outcome studies have demonstrated its validity. The aim of this study was to compare the outcomes of @entity1 who underwent surgical procedures under the care of an anesthesiologist with or without board certification. METHODS: Medicare claims records for 144,883 @entity1 in Pennsylvania who underwent general surgical or orthopedic procedures between 1991 and 1994 were used to determine provider-specific outcome rates adjusted to account for @entity1 severity and case mix, and hospital characteristics. Outcomes of 8,894 cases involving midcareer anesthesiologists, 11-25 yr from medical school graduation, who lacked board certification were compared with all other cases. Midcareer anesthesiologist cases were studied because this group had sufficient time to become certified during an era when obtaining certification was already considered important, and consequently had the highest rate of board certification. Mortality within 30 days of admission and the failure-to-rescue rate (defined as the rate of @entity204 after an in-hospital complication) were the two primary outcome measures. RESULTS: Adjusted odds ratios for @entity204 and failure to rescue were greater when care was delivered by noncertified midcareer anesthesiologists ( @entity204 = 1.13 [95% confidence interval, 1.00, 1.26], P < 0.04; failure to rescue = 1.13 [95% confidence interval, 1.01, 1.27], P < 0.04). Adjusting for international medical school graduates did not change these results. CONCLUSIONS: When anesthesiology board certification is very common, as in midcareer practitioners, the lack of board certification is associated with worse outcomes. However, the poor outcomes associated with noncertified providers may be a result of the hospitals at which they practice and not necessarily their manner of practice.

title: Anesthesiologist board certification and XXXX outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: INTRODUCTION: Recently, multicellular spheroids were isolated from a well-established @entity43 cell line, OVCAR-3, and were propagated in vitro. These spheroid-derived cells displayed numerous hallmarks of @entity5 stem cells, which are chemo- and radioresistant cells thought to be a significant cause of @entity5 recurrence and resultant mortality. Gene set enrichment analysis of expression data from the @entity1 cells and the spheroid-derived putative @entity5 stem cells identified several metabolic pathways enriched in differentially expressed genes. Before this, there had been little previous knowledge or investigation of systems-scale metabolic differences between @entity5 cells and @entity5 stem cells, and no knowledge of such differences in @entity43 stem cells. METHODS: To determine if there were substantial metabolic changes corresponding with these transcriptional differences, we used two-dimensional gas chromatography coupled to mass spectrometry to measure the metabolite profiles of the two cell lines. RESULTS: These two cell lines exhibited significant metabolic differences in both intracellular and extracellular metabolite measurements. Principal components analysis, an unsupervised dimensional reduction technique, showed complete separation between the two cell types based on their metabolite profiles. Pathway analysis of intracellular metabolomics data revealed close overlap with metabolic pathways identified from gene expression data, with four out of six pathways found enriched in gene-level analysis also enriched in metabolite-level analysis. Some of those pathways contained multiple metabolites that were individually statistically significantly different between the two cell lines, with one of the most broadly and consistently different pathways, @entity369 and @entity1521 metabolism, suggesting an interesting hypothesis about @entity5 and stem-like metabolic phenotypes in this pair of cell lines. CONCLUSIONS: Overall, we demonstrate for the first time that metabolism in an @entity43 stem cell line is distinct from that of more differentiated @entity5 cells, supporting the potential importance of metabolism in the differences between @entity5 cells and @entity5 stem cells.

title: XXXX Spheroid-Derived Cells Display Distinct Metabolic Profiles.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'epithelial ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['isogenic cancer', 'cancerous', 'cancer']

entities_list: @entity1521 :: ('CHEBI:26271', 'Chemical') :: ['proline']

entities_list: @entity369 :: ('CHEBI:29016', 'Chemical') :: ['arginine']

answer: @entity1 :: (9606,Species) :: ['OVCAR-3']


abstract: BACKGROUND: In the United States @entity320 is the only individually reported @entity1489 . There are no large state or national registries for @entity1489 . Nevertheless, rare, that is, nonmelanoma, nonepithelial, @entity5 can also be locally aggressive and @entity3 . OBJECTIVES: This study's purpose was to demonstrate that Mohs surgeons can share data to create a rare @entity1489 database. This database may serve as a model for a nationwide database. MATERIALS AND METHODS: We retrospectively reviewed the surgery logs of five Mohs surgery practices in the Houston, Texas, area for rare-nonmelanoma, @entity1489 . A total of 42,279 biopsy-proven @entity5 of the skin treated with Mohs micrographic surgery were reviewed. Tumor data including type, prevalence, year of treatment, and the treating Mohs surgeon(s) were compiled and analyzed. RESULTS: Forty-three types of rare @entity5 were identified. A total of 317 rare @entity5 were treated. No practice saw more than 28 rare @entity5 types. @entity1389 was the rare @entity5 most often treated. CONCLUSIONS: Colleagues can cooperate to create a database of rare @entity5 removed by Mohs micrographic surgery. A range of @entity5 greater than that seen in any single practice is now available for study. This should provide the impetus for a nationwide rare @entity1489 database.

title: A pilot feasibility study of a rare XXXX database.

entities_list: @entity1389 :: ('MESH:C566823', 'Disease') :: ['Atypical fibroxanthoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'tumors']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin tumor', 'nonepithelial-skin cancers', 'nonmelanoma skin cancer', 'skin cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasize']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

answer: @entity1489 :: (MESH:D012878,Disease) :: ['skin tumor']


abstract: Complex I purified from @entity291 heart mitochondria is a multisubunit membrane-bound assembly. In the past, seven of its subunits were shown to be products of the mitochondrial genome, and 35 nuclear encoded subunits were identified. The complex is L-shaped with one arm in the plane of the membrane and the other lying orthogonal to it in the mitochondrial matrix. With mildly chaotropic detergents, the intact complex has been resolved into various subcomplexes. Subcomplex Ilambda represents the extrinsic arm, subcomplex Ialpha consists of subcomplex Ilambda plus part of the membrane arm, and subcomplex Ibeta is another substantial part of the membrane arm. The intact complex and these three subcomplexes have been subjected to extensive reanalysis. Their subunits have been separated by three independent methods (one-dimensional @entity214 -PAGE, two-dimensional isoelectric focusing/ @entity214 -PAGE, and reverse phase high pressure liquid chromatography (HPLC)) and analyzed by tryptic peptide mass fingerprinting and tandem mass spectrometry. The masses of many of the intact subunits have also been measured by electrospray ionization mass spectrometry and have provided valuable information about post-translational modifications. The presence of the known 35 nuclear encoded subunits in complex I has been confirmed, and four additional nuclear encoded subunits have been detected. Subunits B16.6, B14.7, and ESSS were discovered in the @entity214 -PAGE analysis of subcomplex Ilambda, in the two-dimensional gel analysis of the intact complex, and in the HPLC analysis of subcomplex Ibeta, respectively. Despite many attempts, no sequence information has been obtained yet on a fourth new subunit (mass 10,566+/-2 Da) also detected in the HPLC analysis of subcomplex Ibeta. It is unlikely that any more subunits of the @entity291 complex remain undiscovered. Therefore, the intact enzyme is a complex of 46 subunits, and, assuming there is one copy of each subunit in the complex, its mass is 980 kDa.

title: Analysis of the subunit composition of complex I from XXXX heart mitochondria.

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: It has begun to be understood that  -opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in @entity901 -induced @entity16 in @entity35 , @entity1286 and @entity1288 exhibited antinociceptive effects while antinociception of @entity3575 was partial, and such different efficacies might result from the different level of Gi/o protein activation. Based on our background, to reveal further mechanism, we focused on the role of Gi/o protein-related downstream signaling, the @entity50633 ( @entity50633 ) channel. The @entity50633 channel blocker tertiapin-Q (30pmol) was intracerebroventricularly (i.c.v.) or intrathecally (i.t.) administered to @entity35 with @entity901 -induced @entity16 . The antinociception of systemic @entity1286 (3mg/kg, subcutaneously (s.c.)) was suppressed only by pretreatment of i.t. tertiapin-Q, while supraspinal @entity13472 suppressed only the antinociception of systemic @entity1288 (0.56mg/kg, s.c.). Partial antinocicpetion of @entity3575 (0.017mg/kg, s.c.) was neither affected by i.c.v nor i.t. tertiapin-Q. These results demonstrated that @entity50633 channels differentially contribute to antinociceptive effects of MOR agonists, and that action site of @entity50633 channels is also different between @entity1286 and @entity1288 in @entity901 model. This study suggests the possibility that @entity50633 channels have a crucial role for antinociception of MOR agonists in @entity901 -induced @entity16 .

title: @entity1286 and @entity1288 , but not @entity3575 , exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an @entity901 -induced XXXX @entity35 model.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity13472 :: ('MESH:C029738', 'Chemical') :: ['tertiapin-Q']

entities_list: @entity1288 :: ('MESH:D010098', 'Chemical') :: ['oxycodone']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity50633 :: ('50599(Tax:10116)', 'Gene') :: ['G-protein inwardly rectifying K(+)1', 'GIRK1']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

answer: @entity16 :: (MESH:D009422,Disease) :: ['neuropathy']


abstract: BACKGROUND: @entity418 is common in Pakistan. An attempt has been made for the first time to look at the survival data and prognostic factors associated with @entity418 in this region. @entity1 AND METHODS: We did a retrospective review of 263 cases seen at the Aga Khan University Hospital in Karachi. Data analysis was done using the Kaplan-Meier method and the @entity797 proportional hazard model. RESULTS: @entity957 was noted in 81% of the cases, whereas @entity420 was the second most common. At the time of diagnosis, early-stage disease was found in 25%, locally advanced in 41% and metastatic in 34% of all cases. Mean age at diagnosis was 56 years, with 59% males and 41% females. Survival data were available in 89 cases. Median survival was 7 months. On univariate analysis, the following factors were of prognostic significance: obstruction, histology, albumin level at diagnosis, age and platelet count. On multivariate analysis, three factors were found prognostic: presence or absence of @entity957 versus @entity420 and platelet count. CONCLUSIONS: We found that @entity1 with @entity957 and absence of @entity882 and obstruction had a better overall survival. However, this is a limited retrospective analysis; we therefore recommend that these prognostic factors be evaluated in larger studies.

title: Survival data and prognostic factors seen in Pakistani @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'obstruction, squamous cell carcinoma', 'Squamous cell carcinoma']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['Esophageal cancer', 'esophageal cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']


abstract: OBJECTIVE: To explore the efficacy and safety of @entity7274 in the prevention of acute and delayed chemotherapy-induced @entity390 and @entity391 after moderate to severe emetogenic chemotherapy. METHODS: From November 2008 to November 2009, a multicenter, randomized, double-blind and self-crossover phase II clinical trial with a total planned enrollment of 160 @entity1 was carried out to compare @entity7274 (drug A) with @entity19473 (drug B). The subjects were randomized divided into groups AB and BA. The dosing sequence in the group AB was drug A the first cycle and drug B the second cycle while the BA group was administered reversely. The efficacy was evaluated within a period of 5 days after @entity900 or @entity632 -based regimen chemotherapy. Adverse effects were assessed by CTCAE 3.0. RESULTS: Among 155 enrolled cases, 132 cases were assessable for efficacy. The complete control rate of acute chemotherapy-induced @entity390 and @entity391 was 54.55% vs 51.52% for drug A vs drug B (P > 0.05), but that of delayed reaction was 53.03% vs 38.64% respectively. There were significant differences (P = 0.01). Meanwhile, the rate of adverse effects was 4.90% for investigational agent without severe adverse events. The main adverse reactions were @entity10 and @entity1296 . CONCLUSION: With a high safety profile, @entity7274 is an effective agent for the prevention of acute and delayed chemotherapy-induced @entity390 and @entity391 .

title: [Efficacy and safety of @entity7274 versus @entity19473 in the prevention of highly emetogenic chemotherapy-induced @entity391 in Chinese cancer XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity7274 :: ('MESH:C083418', 'Chemical') :: ['palonosetron']

entities_list: @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity19473 :: ('MESH:C045504', 'Chemical') :: ['tropisetron']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Acute @entity1580 requires early diagnosis and prompt surgical intervention. It is not entirely clear whether @entity1 with this form of dissection have clear-cut chest roentgenogram (CXR) patterns or whether the CXR can guide the physician in directing further workup for @entity697 . The purpose of this study is to evaluate the impact of the initial CXR in arousing suspicion for acute @entity1580 . Twelve physicians from four specialties (emergency medicine, radiology, cardiology, and cardiothoracic surgery) evaluated the presenting CXR of ten @entity1 with acute @entity1580 and the CXRs of ten normal individuals in a blinded manner. They were asked whether the CXRs were normal or abnormal (part A) and what the findings were and then were asked whether the CXRs were suspicious for @entity697 (part B) and what the findings were. In part A, of the normal CXRs 81 of 120 (68%) readings were recorded as normal. Of the dissection CXRs 112 of 120 (93%) readings were recorded as abnormal (P < 0.001). In part B, the physicians were asked specifically about suspicion for @entity1580 . Of the normal CXRs 101 of 120 (84%) readings were listed as not suspicious for dissection (i.e., 16% of the normal CXRs were listed as supsicious for dissection). Of the dissection CXRs 88 of 120 (73%) readings were recorded as suspicious for dissection (p < 0.001). The most frequent findings on a dissection CXR when physicians were specifically asked about dissection included widened @entity6830 in 46 of 120 (38%) followed by not suspicious for dissection in 32 of 120 (27%). Among the physician specialties the only statistically significant finding was that the cardiology group was the most likely group to find an abnormality in a "normal" CXR. This data indicates that the presenting CXR is neither sensitive nor specific for @entity697 dissection. In a @entity1 with a suspicious history or physical examination, however, a CXR showing mediastinal widening or other @entity2333 should increase the suspicion for dissection and warrant further workup. Furthermore in a @entity1 with a clinical suspicion a normal CXR reading should not delay echocardiography to rule out type A dissection.

title: The presenting chest roentgenogram in acute XXXX : a multidisciplinary study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute type A', 'acute aortic dissection']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['aortic abnormalities']

entities_list: @entity6830 :: ('MESH:D008479', 'Disease') :: ['mediastinum']

entities_list: @entity1580 :: ('MESH:C562834', 'Disease') :: ['aortic dissection', 'type A aortic dissection']

answer: @entity1580 :: (MESH:C562834,Disease) :: ['type A aortic dissection']


abstract: PURPOSE: To evaluate the outcome of @entity726 valve (AGV) implantation in primary @entity10064 (PCG). METHODS: The medical records of @entity1 with PCG refractory to trabeculotomy and medical therapy who had undergone AGV implantation with a minimum follow-up of 6 months were retrospectively reviewed. The primary outcome measure was cumulative probability of success, defined as intraocular pressure (IOP) of 6-21 mm Hg, with or without medication, and no serious complications, additional @entity726 surgery, or loss of light perception. RESULTS: A total of 33 eyes of 22 @entity1 with a mean age (and standard deviation) of 2.7    3.1 years were included. The @entity1 had a mean follow-up time of 32.6    18.3 months. The mean IOP was 32.8    7.3 mm Hg preoperatively and 16.8    4.0 mm Hg postoperatively. The number of @entity726 medications was 2.5    0.7 preoperatively and 2.2    0.7 postoperatively. The cumulative probability of success (and standard error) was 97%    3.0% in the 1st year, 85%    7.0% in the 2nd year, and 56%    14.8% in the 5th year. When only the first operated eye per @entity1 was included, the cumulative probability of success was 96%    4.4% in the 1st and the 2nd years and 72%    15.3% in the 5th year. Major complications comprised tube-endothelial touch (3 eyes), @entity231 (2 eyes), shunt extrusion (1 eye), and @entity1713 (1 eye). CONCLUSIONS: AGV implantation in @entity1 with PCG offers moderate success in controlling the IOP with a low rate of complications. Most continued to require medications.

title: Results of Ahmed @entity726 in primary XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Ahmed glaucoma', 'glaucoma']

entities_list: @entity10064 :: ('MESH:C565547', 'Disease') :: ['congenital glaucoma']

answer: @entity10064 :: (MESH:C565547,Disease) :: ['congenital glaucoma']


abstract: OBJECTIVE: To determine the effect of functional endoscopic sinus surgery (FESS) on @entity851 in @entity1 . DESIGN: Prospective randomized controlled animal study; retrospective histopathologic study of pediatric FESS specimens. SETTING: Academic tertiary referral medical center. @entity1 : Eight newly weaned piglets; uncinate and ethmoid bone of FESS specimens from 84 @entity1 . INTERVENTIONS: The piglets underwent unilateral FESS. When they had developed to nearly adult size, computed tomography was used to compare facial and sinus development between the surgical and nonsurgical sides. The paranasal sinus contents from @entity1 were histologically examined to analyze bone types with respect to @entity1 age. OUTCOME MEASURES: @entity50 development and @entity851 after FESS in piglets; histologic maturity of sinus bone in @entity1 . RESULTS: Facial growth in piglets was significantly reduced on the side treated by FESS. When compared with the side that did not undergo the operation, growth reached only 57% in the maxillary sinus and 65% in the ethmoid region. @entity1 younger than 9 years had woven (immature) bone; @entity1 9 years and older had predominantly lamellar (mature) bone. CONCLUSIONS: This preliminary study shows that even limited surgery in the anterior ethmoid region can affect sinus and facial growth in the piglet. Review of corresponding @entity1 histologic specimens suggests that further investigation is warranted to rule out the possibility of facial and sinus growth disturbance after this surgery in @entity1 .

title: XXXX and facial growth after pediatric endoscopic sinus surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'human', 'Children', 'patient', 'PARTICIPANTS']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['facial skeletal growth']

answer: @entity50 :: (MESH:D012851,Disease) :: ['Sinus']


abstract: AIM OF THE STUDY: @entity14 ( @entity14 ) is one of the leading cause of @entity204 in European population. It progresses without any symptoms in the early stages or those clinical symptoms are very discrete. The aim of this study was a retrospective analysis of treatment outcomes in @entity1 with @entity14 complicated with intestinal perforation. MATERIAL AND METHODS: A retrospective analysis of @entity1 urgently operated upon in our Division of General Surgery, because of large intestine perforation, from February 1993 to February 2013 has been made. Results were compared with a group of @entity1 undergoing the elective surgery for @entity14 in the same time and Division. RESULTS: Intestinal perforation occurred more often in males (6.52% vs. 6.03%), @entity1 with mucous component in histopathological examination (9.09% vs. 6.01%) and with clinicaly advanced @entity14 . @entity1 treated because of perforation had a five-fold higher 30 day mortality rate (9.09% vs. 1.83%), however long-term survival did not differ significantly in both groups. After resectional surgery in 874 @entity1 an intestinal @entity254 was made. @entity834 was present in 23 (2.6%) @entity1 . This complication occurred six-fold more frequently in a group of @entity1 operated upon because of intestinal perforation (12.20% vs. 2.16%). CONCLUSIONS: In @entity1 with @entity14 complicated with perforation of the colon in a 30-day observation significantly higher rate of complications and mortality was shown, whereas there was no difference in distant survival rates.

title: XXXX with intestinal perforation - a retrospective analysis of treatment outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['Anastomotic leakage']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'CRC', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['Colorectal cancer']


abstract: Postemergent salmonid fry experience a "critical period" in their development, during which there may be a high mortality rate, so determining the long-term success of the year class. The mechanism(s) underlying this phenomenon are not fully understood but physiological stress may be a contributory factor. This study sought to establish at what point in their development, posthatch, salmonids become stress responsive in terms of activation of the @entity2339 . Immunoreactive @entity288 were measured in tissue extracts of @entity5660 at intervals from 4 weeks prehatch to 27 weeks posthatch and in brown trout from 5 to 22 weeks posthatch. @entity288 were detectable throughout this period in both species. Simultaneous determination of whole-body immunoreactive @entity228 levels (IRC) and plasma @entity701 levels in fingerling trout validated the use of whole-body levels as an indicator of stress-induced elevation of corticosteroids. However, the dynamics of the circulating @entity701 response to stress were not fully conveyed by whole-body measurements. From 5 weeks posthatch IRC increased significantly within 30-60 min following mechanical disturbance and confinement, suggesting a functional @entity2339 to be present. An ectoparasite (Ichthyobodo sp.) infestation during this period caused a substantial increase in IRC levels in both species indicating that the @entity2339 in these fish was sensitive to naturally occurring stressors. The response of fry to acute and chronic stress resembled that of adult fish in terms of duration. These data indicate that the early pre- and postemergent stages of salmonid fish are likely to be able to benefit from the adaptive advantage of @entity2339 activation during episodes of acute stress but may also be susceptible to the deleterious consequences of prolonged activation of the @entity2339 under conditions of chronic stress.

title: The corticosteroidogenic response of brown and XXXX alevins and fry to environmental stress during a "critical period".

entities_list: @entity5660 :: ('8022', 'Species') :: ['rainbow trout']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['HPI', 'HPI axis', 'hypothalamic-pituitary-interrenal (HPI) axis']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids', 'Corticosteroids']

answer: @entity5660 :: (8022,Species) :: ['rainbow trout']


abstract: OBJECTIVE: To compare preoperative administration of @entity9213 and @entity12691 to perioperative administration of @entity12691 alone for control of postoperative signs of @entity158 in @entity235 . ANIMALS: 40 client-owned @entity235 scheduled for surgical repair of a cranial cruciate @entity397 . PROCEDURE: Group-1 @entity235 received @entity12691 (0.2 mg/kg, IV) and @entity9213 (0.2 mg/kg, IV) just prior to surgery. Group-2 @entity235 received @entity12691 just prior to surgery (0.2 mg/kg, IV) and at incision closure (0.1 mg/kg, IV). @entity158 assessment began 1 to 2 hours before surgery and from extubation until 24 hours after surgery by obtaining the following measurements: the visual analog scale (VAS) score, @entity158 score (CPS), adjusted @entity158 score, modified @entity158 score, and the adjusted modified @entity158 score (AMCPS). Serum @entity701 concentration was measured between 12 to 24 and between 1 to 2 hours prior to surgery, and at 30 minutes, and 1, 2, 4, 8, 18, and 24 hours after extubation. RESULTS: No significant differences between treatment groups were observed in CPS or VAS score. At 8, 9, 10, and 11 hours after extubation, @entity9213 - @entity12691 -treated @entity235 had a significantly lower AMCPS, compared with @entity12691 -alone-treated dogs. Total serum @entity701 concentration (area under the curve) during the measurement period was significantly lower in @entity9213 - @entity12691 -treated @entity235 , compared with @entity12691 -alone treated @entity235 . CONCLUSIONS AND CLINICAL RELEVANCE: Preoperative single dose administration of @entity9213 - @entity12691 is equivalent to or slightly better than the administration of 2 perioperative doses of @entity12691 for the control of postoperative signs of @entity158 in @entity235 .

title: Evaluation of intravenous administration of @entity9213 for perioperative XXXX management following stifle joint surgery in @entity235 .

entities_list: @entity12691 :: ('MESH:D002077', 'Chemical') :: ['butorphanol']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ligament rupture']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'cumulative pain', 'pain']

entities_list: @entity9213 :: ('MESH:C065757', 'Chemical') :: ['meloxicam']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: BACKGROUND: With conventional blunt surgical resection of @entity5 , local recurrence rates are high and the individual surgeon putatively influences @entity1 outcome. With @entity348 ( @entity348 ) local recurrence rates have been reduced and intersurgeon variability may be less important. The ' @entity348 project' was a collaborative project that included surgical workshops in Stockholm between 1994 and 1997. The aim of this study was to assess the impact of the project on the practice of @entity5 surgery in Stockholm and to analyse whether surgeon case volume and participation in the workshops influenced @entity1 outcome. METHODS: All 652 @entity1 who had an abdominal resection for @entity5 in Stockholm between 1995 and 1997 were included. Outcome was compared in @entity1 operated on by teams that included high-volume surgeons (more than 12 operations per year) with teams that included low-volume surgeons (12 operations or fewer per year), as well as between teams that including workshop @entity1 and non- @entity1 . RESULTS: Forty-six surgeons operated on the 652 @entity1 . Five high-volume surgeons operated on 48 per cent of the @entity1 . In these, outcome was significantly better than in @entity1 treated by low-volume surgeons (local recurrence rate 4 versus 10 per cent (P = 0.02); rate of @entity5 death 11 versus 18 per cent (P = 0.007)). Twenty-six surgeons were workshop @entity1 and performed 93 per cent of the operations. Radiotherapy, @entity348 and sphincter-preserving surgery were more common among @entity1 treated by workshop @entity1 . CONCLUSION: The @entity348 project has had an impact on @entity5 surgical practice in Stockholm. Variability in @entity1 outcome was mainly related to case volume, with better results obtained in @entity1 treated by high-volume surgeons.

title: The surgeon as a prognostic factor after the introduction of @entity348 in the treatment of XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['TME', 'total mesorectal excision']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: UNASSIGNED: It has been demonstrated that a vegetarian diet may be effective in reducing body weight, however, the underlying mechanisms are not entirely clear. We investigated whether there is a difference in resting energy expenditure between 26 vegetarians and 26 non-vegetarians and the correlation between some nutritional factors and inflammatory markers with resting energy expenditure. In this cross-sectional study, vegetarians and non-vegetarians were matched by age, body mass index and gender. All underwent instrumental examinations to assess the difference in body composition, nutrient intake and resting energy expenditure. Biochemical analyses and 12 different cytokines and growth factors were measured as an index of inflammatory state. A higher resting energy expenditure was found in vegetarians than in non-vegetarians (p = 0.008). Furthermore, a higher energy from diet, fibre, vegetable @entity10392 intake and interleukin-b ( @entity1356 ) was found between the groups. In the univariate and multivariable analysis, resting energy expenditure was associated with vegetarian diet, free-fat mass and vegetable @entity10392 (p < 0.001; Slope in statistic (B) = 4.8; b = 0.42). After adjustment for cytokines, log10 @entity688 ( @entity688 ) still correlated with resting energy expenditure (p = 0.02). Resting energy expenditure was positively correlated with a specific component of the vegetarian's diet, i.e., vegetable @entity10392 . Furthermore, we showed that @entity688 was positively associated with resting energy expenditure in this population.

title: High Vegetable XXXX Intake Is Associated with High Resting Energy Expenditure in Vegetarians.

answer: @entity10392 :: (118611,Gene) :: ['Fats']


abstract: UNASSIGNED: @entity463 ( @entity463 ) is one of the most common @entity5 . Due to a high recurrence rate and a lack of effective treatments, the average survival rate remains low. @entity2903 ( @entity2904 ), a class of alkylating agent, is widely used as a first-line therapeutic drug during the adjuvant treatment for @entity463 @entity1 . However, most @entity1 exhibit a palpable resistance to @entity2904 treatment. Additionally, the underlying mechanism remains to be clarified. In this study, @entity2041 ( @entity2197 ) and reactive @entity26 species (ROS) levels were found to be closely associated with the sensitivity of @entity463 cells to @entity2904 . We also found that @entity2904 markedly induced @entity9325 , the subunit of @entity2227 / @entity1434 transporter system xc- expression, which together with the @entity2197 synthesis was increased while the @entity2904 -inducible ROS level was decreased in @entity463 cells. In addition, the @entity3959 y-lyase (CTH) acivity, a key enzyme in the transsulfuration pathway was enhanced by @entity2904 , which insured a @entity462 supply and @entity2197 synthesis in a compensatory manner when @entity9325 was blocked. Thus, the individual inhibition of @entity9325 by siRNA and a pharmacological inhibitor ( @entity3378 ) only partially inhibited @entity2197 synthesis and moderately enhanced the @entity463 cell sensitivity to @entity2904 . However, the @entity2904  -induced @entity137 was markedly increased along with a marked decrease in @entity2197 levels as result of co-treatment with @entity66095 , which inhibited @entity462 uptake from @entity9325 transporter and suppressed CTH activity, leading to impaired transformation from @entity1853 to @entity462 . In conclusion, to @entity463 therapy with a drug combination of @entity2904 and erastin may be beneficial.

title: Erastin sensitizes @entity463 cells to XXXX by restraining @entity9325 and @entity3959 -y-lyase function.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['encephalic malignant tumors']

entities_list: @entity3959 :: ('MESH:D003540', 'Chemical') :: ['cystathionine']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity1853 :: ('MESH:D008715', 'Chemical') :: ['methionine']

entities_list: @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'Glioblastoma multiforme']

entities_list: @entity3378 :: ('MESH:D012460', 'Chemical') :: ['sulfasalazine']

answer: @entity2903 :: (MESH:C047246,Chemical) :: ['temozolomide']


abstract: PURPOSE: To investigate the roles of @entity320 -associated macrophages in @entity320 resistance to @entity817 inhibitors (BRAFi). EXPERIMENTAL DESIGN: An in vitro macrophage and @entity320 cell coculture system was used to investigate whether macrophages play a role in @entity320 resistance to BRAFi. The effects of macrophages in @entity5 resistance were examined by proliferation assay, cell death assay, and Western blot analyses. Furthermore, two @entity19 preclinical models were used to validate whether targeting macrophages can increase the antitumor activity of BRAFi. Finally, the number of macrophages in @entity320 tissues was examined by immunohistochemistry. RESULTS: We demonstrate that in @entity817 -mutant @entity320 , BRAFi paradoxically activate the mitogen-activated protein kinase (MAPK) pathway in macrophages to produce @entity7 , which reactivates the MAPK pathway and stimulates cell growth in @entity320 cells. Blocking the MAPK pathway or @entity7 signaling then reverses macrophage-mediated resistance. Targeting macrophages increases the antitumor activity of BRAFi in @entity19 and @entity1 @entity5 models. The presence of macrophages in @entity320 predicts early relapse after therapy. CONCLUSIONS: Our findings demonstrate that macrophages play a critical role in @entity320 resistance to BRAFi, suggesting that targeting macrophages will benefit @entity1 with @entity817 -mutant @entity320 .

title: @entity817 Inhibition Stimulates Melanoma-Associated Macrophages to Drive XXXX Growth.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanomas']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Tumor']


abstract: BACKGROUND: Pemetrexed is a commonly used treatment for @entity902 -resistant advanced @entity189 ( @entity189 ) based on objective response rates of 8% and 28% in two small phase II studies. To address the discrepancy in reported response rates and to assess efficacy and @entity137 outside of a clinical trial setting, we performed a large retrospective analysis of pemetrexed use at Memorial Sloan Kettering Cancer Center. We also investigated candidate prognostic factors for overall survival in this setting to explore whether the neutrophil-lymphocyte ratio (NLR) had independent prognostic significance. @entity1 AND METHODS: @entity1 receiving pemetrexed for @entity902 -resistant advanced @entity189 between 2008 and 2013 were identified. The Response Evaluation Criteria in @entity5 (RECIST, version 1.1) were used to determine response rate. Kaplan-Meier and Cox regression analyses were used to examine the association of various factors with efficacy and survival outcomes. @entity1503 and @entity854 were recorded. RESULTS: One hundred and twenty-nine @entity1 were treated with pemetrexed. The objective response rate was 5% (95% confidence interval: 1%-9%), and the median duration of response was 8 months. Median progression-free survival (PFS) was 2.4 months, and the 6-month PFS rate was 14%. There was no significant difference in response rate by age, Eastern Cooperative Oncology Group (ECOG) performance status, or number of prior therapies. On multivariable analysis, ECOG performance status (p < .01), liver metastases (p = .02), and NLR (p < .01) had independent prognostic significance for overall survival. CONCLUSION: This 129- @entity1 series is the largest reported data set describing pemetrexed use in advanced @entity189 . Activity was modest, although discovery of molecular biomarkers predictive of response would be valuable to identify the small subset of @entity1 who do gain significant benefit. Overall, the data highlight the urgent need to develop novel therapies for these @entity1 .

title: The Safety and Efficacy of Single-Agent Pemetrexed in XXXX -Resistant Advanced @entity189 : A Large Single-Institution Experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Solid Tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma', 'UC']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematologic toxicity']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['laboratory abnormalities']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity902 :: (MESH:D010984,Chemical) :: ['Platinum']


abstract: @entity5555 ( @entity5555 ) is a hallmark of most @entity5 cells. However, compared to most @entity1 @entity5 cell types, the @entity995 cells show a relatively stable genome. The fundamental basis of this genomic stability has yet to be elucidated, and the role of certain proteins involved in cell cycle regulation may be the key to the development of these specific genotypes. We examined whether thyroid hormone receptor beta 1 and 2 ( @entity14960 and @entity67123 ), known to regulate tumorigenesis, and @entity38685 , a mitotic checkpoint protein, play a role in maintaining genomic stability in @entity995 . In order to elucidate the role of these proteins in development of @entity5700 , an indicator of @entity5555 , we first studied comparative @entity5555 in @entity995 and multiple @entity995 mutant @entity5 cell lines using single nucleotide polymorphism (SNP) analysis. We then utilized pLKO lentiviral vectors to selectively modify expression of the targeted cell cycle proteins and interpret their effect on downstream cell cycle proteins and their relative effects on the development of @entity5 cell lines. The SNP analysis showed that @entity995 displayed relatively fewer genomic copy number changes as compared to other @entity996 -deficient @entity5 cell lines. Both @entity14960 and @entity67123 knockdown led to accumulation of @entity16262 and @entity38685 and increased @entity5555 as demonstrated by an increase in polyploidy. Downregulation of @entity38685 led to a relative decrease in @entity5555 while upregulation of @entity38685 led to a relative increase in @entity5555 . Knockdown of @entity16262 led to a downstream decrease in @entity38685 expression. Rb_ knockdown also upregulated @entity16262 and @entity38685 leading to increased @entity5555 . We showed that Rb is necessary for @entity38685 inhibition and genomic stability. A relatively stable genome in @entity995 cells is maintained by @entity14960 and @entity67123 -mediated @entity38685 inhibition, counteracting Rb_ @entity5555 . @entity14960 , @entity67123 and Rb_ KD all led to the downstream @entity38685 accumulation, apparently through an activation of @entity16262 resulting in extensive genomic instability as seen in other @entity5 .

title: @entity5555 and proliferation/survival pathways in XXXX -deficient @entity5 .

entities_list: @entity5700 :: ('MESH:D011123', 'Disease') :: ['aneuploidy/polyploidy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['polyploidy in multiple tumor', 'cancer', 'Rb-deficient tumors']

entities_list: @entity5555 :: ('MESH:D042822', 'Disease') :: ['GIN', 'Genomic instability', 'deficiency-related GIN']

entities_list: @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma tumor', 'retinoblastoma', 'RB', 'retinoblastomas']

answer: @entity996 :: (5925,Gene) :: ['RB1']


abstract: AIMS: Interaction of vascular and metabolic factors appears to contribute to the pathogenesis of @entity3949 . The aim of the study was to assess the impact of arterial stiffening and @entity121 on @entity3949 in @entity164 2 @entity6 . METHODS: In 294 @entity1 with @entity164 2 @entity6 , @entity16 was assessed by four components: the presence of @entity1109 , the absence of ankle tendon reflexes, perception of vibration scores and heart rate variation. We measured @entity121 ( @entity121 ) of carotid arteries to assess arterial thickening, and brachial-ankle pulse-wave velocity ( @entity122 ) and brachial pulse pressure (PP) which reflect arterial stiffening. RESULTS: @entity3949 , defined as > or = two of the four components, was significantly associated with age, duration, glycated haemoglobin (HbA(1c)), systolic blood pressure, diastolic blood pressure, PP, @entity101 , @entity989 , urinary albumin excretion rate, @entity8 stages, @entity122 and @entity121 . @entity122 and PP were significantly associated with @entity16 independent of conventional cardiovascular risk factors. Multiple logistic regression analysis revealed that @entity122 , @entity989 , age, and HbA(1c), were significant independent @entity16 . CONCLUSIONS: The present cross-sectional study indicates that markers for vascular wall properties such as @entity122 , @entity121 and PP are significantly associated with @entity3949 . @entity122 and PP are significant @entity16 independent of conventional cardiovascular risk factors. Multifactorial intervention to inhibit progression of the @entity731 process may slow progression of @entity16 .

title: @entity3949 is closely associated with arterial stiffening and @entity121 in @entity164 2 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['determinants of neuropathy', 'neuropathy']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['neuropathic symptoms']

entities_list: @entity3949 :: ('MESH:D003929', 'Disease') :: ['diabetic neuropathy', 'Diabetic neuropathy']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['IMT', 'thickness', 'intima-media thickness']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: @entity4104 ( @entity4104 ) is an important cellular effector in the Jak/STAT signaling pathway, which plays a pivotal role in @entity1 immune system regulation, mediating the effect of different cytokines. In the present study, we assessed the correlation between @entity4104 polymorphisms ( @entity67857 @entity6344 and @entity20274 @entity4866 ) and risk of the @entity1669 ( @entity1669 ) @entity2621 ( @entity2621 ) and @entity2743 ( @entity2743 ) in the Polish population. Moreover, we evaluated the association of polymorphisms with the thyroid autoantibody levels (TPOAb, TgAb, TRAb) and the correlation between circulating proinflammatory @entity650 and @entity4155 cytokines and thyroid autoantibody levels. The study included 71 AITD @entity1 with @entity2621 (n = 39) or @entity2743 (n = 32) and a control group (n = 40). DNA SNP genotyping was performed using TaqMan probes. Serum levels of thyroid autoantibodies, @entity650 and @entity4155 were measured according to enhanced chemiluminescence (ECL) assay. Allele A of @entity4104 SNP @entity20274 @entity4866 was significantly more frequent in both @entity2621 and @entity2743 @entity1 , while allele G was significantly more frequent in the control group. Similarly, allele C and CC genotype of @entity4104 SNP @entity67857 @entity6344 were significantly more frequent in the control group in comparison to @entity2621 and @entity2743 @entity1 . Significantly higher TgAb median values were associated with CT @entity67857 genotype in @entity2621 patients. Serum levels of @entity650 and @entity4155 positively correlated with TPOAb in the @entity2621 group. Serum level of @entity650 positively correlated with TPOAb in the AITD group. Both studied polymorphisms seem to play a significant role in susceptibility to AITD ( @entity2621 and @entity2743 ). @entity4104 SNPs may influence TAb level in AITD @entity1 .

title: Single nucleotide polymorphisms in the @entity4104 gene influence AITD susceptibility, thyroid autoantibody levels, and @entity650 and XXXX secretion.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6344 :: ('c|SUB|C||T', 'DNAMutation') :: ['C>T']

entities_list: @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease", 'GD']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroid diseases', 'AITDs']

entities_list: @entity4104 :: ('6774', 'Gene') :: ['STAT3', 'signal transducer and activator of transcription 3']

entities_list: @entity2621 :: ('MESH:D050031', 'Disease') :: ['HT', "Hashimoto's thyroiditis"]

entities_list: @entity4866 :: ('c|SUB|A||G', 'DNAMutation') :: ['A>G']

answer: @entity4155 :: (3605,Gene) :: ['IL17']


abstract: BACKGROUND: @entity10227 ( @entity500 and @entity4446 ) remain integral to most medical strategies for maintaining remission in @entity30 ( @entity30 ) and @entity31 ( @entity31 ). Indefinite use of these drugs is tempered by long-term risks. While clinical relapse is noted frequently following drug withdrawal, there are few published data on predictive factors. AIM: To investigate the success of planned @entity10227 withdrawal in @entity1 in sustained clinical remission to identify rates and predictors of relapse. METHODS: This was a multicentre retrospective cohort study from 11 centres across the UK. @entity1 included had a definitive diagnosis of @entity8787 , continuous @entity10227 use >= 3  years and withdrawal when in sustained clinical remission. All @entity1 had a minimum of 12  months follow-up post drug withdrawal. Primary and secondary end points were relapse at 12 and 24  months respectively. RESULTS: 237 @entity1 were included in the study (129 @entity30 ; 108 @entity31 ). Median duration of @entity10227 use prior to withdrawal was 6.0  years (interquartile range 4.4-8.4). At follow-up, moderate/severe relapse was observed in 23% @entity30 and 12% @entity31 @entity1 at 12  months, 39% @entity30 and 26% @entity31 at 24  months. Relapse rate at 12  months was significantly higher in @entity30 than @entity31 (P  =  0.035). Elevated CRP at withdrawal was associated with higher relapse rates at 12  months for @entity30 (P  =  0.005), while an elevated white cell count was predictive at 12  months for @entity31 (P  =  0.007). CONCLUSION: @entity10227 withdrawal in the context of sustained remission is associated with a 1-year moderate-to-severe relapse rate of 23% in @entity30 and 12% in @entity31 .

title: XXXX withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity4446 :: ('MESH:D015122', 'Chemical') :: ['mercaptopurine']

entities_list: @entity10227 :: ('CHEBI:35666', 'Chemical') :: ['Thiopurine', 'Thiopurines', 'thiopurine']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity10227 :: (CHEBI:35666,Chemical) :: ['Thiopurine']


abstract: OBJECTIVE: The study explored the phenomenology and prognostic significance of delusions in @entity308 . METHOD: From 452 @entity1 with @entity308 , we selected those with at least one belief fulfilling both DSM-III prerequisites for a delusion (i.e., being of "delusional proportions" and being maintained with "delusional intensity"). These @entity1 were compared to the others with respect to demographic, historical, and index episode features; time spent in a @entity308 during a prospective observation period; and 10-year outcome. The same comparisons were made between @entity1 with @entity1833 and those with mood-congruent delusions only. The study covered the period between January 1, 1978, and December 31, 2005. RESULTS: About 20% of @entity1 had at least one delusion in their index episode. An additional 5.3% had a belief fulfilling only one of the DSM-III prerequisites for a delusion. In about one quarter of delusional @entity1 , the index episode was not "severe." Almost 10% of delusional @entity1 had both mood-congruent and @entity1833 . In @entity1 with delusions, time to syndromal recovery from index episode was longer and antipsychotic medication was more frequently used (both p < .0001). The presence of delusions predicted a higher depressive morbidity during the prospective observation period (p < .05), but not a poorer 10-year outcome. No variable discriminated @entity1 with @entity1833 from those with mood-congruent delusions only. CONCLUSION: The presence of delusions in a major @entity308 has significant therapeutic and short-term prognostic implications. However, the boundary between delusions and nondelusional sustained preoccupations is somewhat fuzzy, and some DSM-IV assumptions concerning @entity308 (i.e., that this @entity308 is always "severe"; that in an individual @entity1 , delusions will be either all congruent or all incongruent with @entity308 mood; and that @entity1833 are associated with a poorer prognosis) may be unwarranted.

title: Phenomenology and prognostic significance of delusions in XXXX : a 10-year prospective follow-up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed', 'depression', 'major depressive disorder', 'psychotic depression', 'DSM-III major depression', 'depressive episode']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['mood-incongruent delusions']

answer: @entity308 :: (MESH:D003866,Disease) :: ['major depressive disorder']


abstract: In order to reach the purpose of co-transferring double drug resistance genes into @entity1 @entity2280 (+) progenitor cells to broaden the spectrum of drug resistance, the expression efficiency of @entity1 @entity1262 ( @entity1262 ) gene mediated by the internal ribosomal entry site (IRES) was investigated. Two retroviral vectors were transferred into packaging cells. One is @entity21186 -DIM containing double drug resistance genes, in which the translation of @entity1262 gene was controlled under an IRES from @entity9258 . The other is @entity21186 - @entity1262 which only contains @entity1262 gene controlled under the same promoter of @entity21186 -DIM. The amphotropic retroviral packaging cells PA317/ @entity21186 -DIM and PA317/ @entity21186 - @entity1262 were obtained with titer of 8 x 10(4) and 1.3 x 10(5) cfu/ml respectively. @entity1 cord blood @entity2280 (+) cells were transduced by supernatant infection. Expression of @entity7895 was detected by flow cytometry. Compared with the untransduced group, the expression of @entity7895 in @entity21186 -DIM transduced group and @entity21186 - @entity1262 transduced group was elevated 10.92% and 28.82% respectively. However, the expression of @entity7895 in @entity21186 - @entity1262 transduced group was higher than that in @entity21186 -DIM transduced group. The result suggests that @entity1262 gene can express in the @entity1 progenitor cells under control of IRES. It laid the foundation of subsequence research. The reason on the difference in @entity1262 gene expression efficiency between @entity21186 - @entity1262 transduced group and @entity21186 -DIM transduced group need further research.

title: [Internal Ribosomal Entry Site-Mediated Expression of @entity1 @entity1262 Gene in @entity1 XXXX (+) Cells]

entities_list: @entity1262 :: ('5243', 'Gene') :: ['MDR1', 'multidrug resistance 1']

entities_list: @entity9258 :: ('12104', 'Species') :: ['encephalomyocarditis virus']

answer: @entity2280 :: (947,Gene) :: ['CD34']


abstract: OBJECTIVES: Recent advances in endoscopic technology have allowed its application to middle ear surgery. An antifog agent is necessary for endoscopy because moisture and blood may obscure visibility. Ultrastop is one of the most commonly used antifog agents. The current study examined the @entity2167 effect of topical application of Ultrastop in the @entity840 ear. STUDY DESIGN: A preliminary experimental animal study. SETTING: University hospital. SUBJECTS AND METHODS: Eighteen male Hartley @entity840 (weight, 480-620 g) were divided into 3 groups to be treated with Ultrastop, @entity801 (50 mg/mL, positive control), or saline solution (negative control). After auditory brainstem responses were measured, topical solutions of 0.2 mL were applied through a small hole made at the @entity4530 . Posttreatment auditory brainstem responses were obtained 14 days after the treatment. The extent of @entity2169 was investigated and scored. RESULTS: The saline-treated group showed no deterioration in auditory brainstem response threshold. The Ultrastop-treated and @entity801 -treated groups showed severe deterioration in auditory brainstem response threshold. Middle ear examination revealed extensive changes in the Ultrastop-treated group and medium changes in the @entity801 -treated group. CONCLUSION: Ultrastop applied topically to the @entity840 middle ear caused significant @entity2172 and @entity393 .

title: XXXX effect of ultrastop antifog solution applied to the @entity840 middle ear.

entities_list: @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin']

entities_list: @entity2172 :: ('MESH:D010033', 'Disease') :: ['middle ear inflammation']

entities_list: @entity4530 :: ('MESH:D001768', 'Disease') :: ['tympanic bulla']

entities_list: @entity840 :: ('10141', 'Species') :: ['guinea pigs', 'guinea pig']

entities_list: @entity2169 :: ('MESH:D004427', 'Disease') :: ['middle ear damage']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing impairment']

answer: @entity2167 :: (MESH:D006311,Disease) :: ['Ototoxic']


abstract: @entity2348 has been recognized as a rare disease since the development of antibiotics. Usually, the disease is associated with underlying conditions or a seeding of infection elsewhere to the pericardium. Here we describe a case of group G @entity883 as an initial presentation of @entity694 . A 52-yr-old @entity1 was admitted because of @entity1353 . An electrocardiogram showed a diffuse ST-segment elevation and a two-dimensional echocardiogram showed a large amount of @entity2294 . A pericardiocentesis was done and purulent fluid was drained. Group G streptococci was cultured in pericardial fluid. The @entity1 was treated with antibiotics and pericardiostomy with saline irrigation. A colonoscopy revealed a small mass with moderately differentiated @entity694 . He underwent a mucosectomy and was recovered without any complication.

title: Purulent pericarditis caused by group G streptococcus as an initial presentation of XXXX .

entities_list: @entity883 :: ('MESH:D013290', 'Disease') :: ['streptococcal pericarditis']

entities_list: @entity2294 :: ('MESH:D010490', 'Disease') :: ['pericardial effusion']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['Bacterial pericarditis']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'adenocarcinoma in rectosigmoid colon']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colon cancer']


abstract: PURPOSE: This multicenter pilot study assessed the feasibility and efficacy of a time-intensified @entity1732 , @entity2879 , @entity632 , @entity786 , @entity1891 , @entity4174 , and @entity229 (BEACOPP) regimen given in 14-day intervals (BEACOPP-14) with @entity1261 ( @entity1261 ) support in advanced @entity978 . @entity1 AND METHODS: From July 1997 until March 2000, 94 @entity1 with @entity978 stage @entity39638 , III, and IV were scheduled to receive eight cycles of BEACOPP-14. Consolidation radiotherapy was administered to regions with @entity66 or @entity41 after chemotherapy. RESULTS: All @entity1 were assessable for @entity137 and treatment outcome. Eighty-six @entity1 received the planned eight cycles of BEACOPP-14. Consolidation radiotherapy was given in 66 @entity1 . Chemotherapy could generally be administered on schedule. Dose reductions varied among drugs but were generally low. Acute @entity137 was moderate, with World Health Organization grade 3/4 @entity1431 in 75%, @entity882 in 23%, @entity417 in 65%, and @entity281 in 12% of @entity1 . A total of 88 @entity1 (94%) achieved a complete remission. Four @entity1 had progressive disease. At a median observation time of 34 months, five @entity1 have relapsed, one @entity1 developed a secondary @entity1893 , and three @entity204 were documented. The overall survival and freedom from treatment failure rates at 34 months were 97% (95% confidence interval [CI], 93% to 100%) and 90% (95% CI, 84% to 97%), respectively. CONCLUSION: Acceleration of the BEACOPP baseline regimen by shortening cycle duration with @entity1261 support is feasible and effective with moderate acute @entity137 . On the basis of these results, the German @entity978 Study Group will compare the BEACOPP-14 regimen with BEACOPP-21 escalated in a prospective multicenter randomized trial.

title: 14-day variant of the @entity1732 , @entity2879 , @entity632 , XXXX , @entity1891 , @entity4174 , and @entity229 regimen in advanced-stage @entity978 : results of a pilot study of the German @entity978 Study Group.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients', 'PATIENTS']

entities_list: @entity4174 :: ('MESH:D011344', 'Chemical') :: ['procarbazine']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor', 'G-CSF']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['initial bulky disease']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's Lymphoma", "Hodgkin's lymphoma"]

answer: @entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']


abstract: UNASSIGNED: 168 Background: SCPs may address inadequate provider-to-provider communication but @entity298 views regarding EHR-generated SCPs have not been assessed. A multiple choice survey was used to evaluate an EHR-generated SCP for appropriate content, length, perceived accuracy, need for updates and preferred method of delivery (the Clinican survEy of Care Plan [ChECkuP]). METHODS: PCPs were recruited from the Wisconsin Research and Education Network (WREN), a cohort of family practitioners working in urban and rural Wisconsin. WREN practitioners were e-mailed and invited to participate if they currently saw @entity1 with a @entity0 history. PCPs were provided a sample 10-page EHR-generated SCP and completed the ChECkuP at one time point. RESULTS: 36 PCPs participated in Summer 2014. Most PCPs reported the sample EHR-generated SCP as accurate (75%), easy to use (58%) and useful in coordinating care (75%). Few felt using SCPs would disrupt their clinic workflow (11%) or that SCP use would take too much time (14%). Most (75%) preferred receiving SCPs via EHR, vs paper (36%), having the @entity1 provide (19%) or viewing the SCP on an external website (6%). Most deemed consistent provision (69%) and standard location (78%) important. With regards to timing, 42% reported desiring an SCP immediately after completion of primary treatment. However, PCPs requested some changes: 33% requested a shorter SCP (ideally 1-3 pages) and 53% advocated for SCPs specifically written for PCPs rather than producing one document for both @entity298 and survivor. Also, most (53%) felt that SCPs should be updated based on information changes rather than on a regular schedule, including changes to screening guidelines (100%), late or long term side effects (89%) and followup recommendations (95%). CONCLUSIONS: PCPs regarded EHR-generated SCPs as useful in coordinating care between oncologists and primary care. PCPs desired a standardized SCP accessible within the EHR. EHR-generated SCP content, length and layout will be revised based on the feedback provided. CLINICAL TRIAL INFORMATION: OS12122.

title: @entity298 ( XXXX ) views on survivorship care plans (SCPs) generated by an electronic health record (EHR).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity298 :: (MESH:D010538,Disease) :: ['PCP']


abstract: INTRODUCTION: @entity2909 , which usually occur multilocular in uterus, can develop even if rarely in other organs with smooth muscle cells. The @entity5 is considered benign; 2 case reports supports the hypothesis that @entity1868 could metastasize, and in the @entity3 sites grow invasively. METHODS: 2 female @entity1 44 y. and 29 y. old were admitted to our clinic for @entity20096 . Due to increasing @entity5 size respectively dypnea, they were operated on. Multiple nodules of the left lung in one case, and a mediastinal @entity5 in the other were resected; resected @entity5 was histologically examined. RESULTS: In both cases it was a matter of well-differentiated @entity1822 . The mediastinal @entity5 has already invade the N. phrenicus. Postoperatively there were no complications. @entity1 discharged in well-doing state, medical control one year later revealed no new growth. CONCLUSION: @entity358 are rare, they occur in sexually mature @entity1 in coincidence with @entity1868 . Even though many authors assume that @entity20096 is a lung @entity3 of @entity5 , the pathogenesis is still hypothetical. Supporting this thesis is the hormone dependence of both the uterine and the @entity5 ; against it, is that extrapulmonary locations are too rarely observed. The still open pathogenetical question has no therapeutical consequence. Whenever technically possible, a radical, parenchyma-saving surgical therapy should be the first choice. Otherwise hormon-ablation is a good alternative.

title: @entity358 in XXXX after @entity1868 . Benign metastasizing @entity2909 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'pulmonary tumours', 'benign tumours', 'tumour']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['Multiple pulmonary leiomyomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1868 :: ('MESH:D009214', 'Disease') :: ['uterus myoma']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['Leiomyomas']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND AND OBJECTIVES: The anterior approach for celiac plexus block has the potential risks of @entity281 , @entity548 , and @entity292 formation. We report a case of a @entity1 who developed a @entity733 with the formation of a vascular-enteric @entity292 after a @entity616 from the anterior approach. CASE REPORT: A 60-year-old female with a history of @entity158 secondary to chronic idiopathic calcifying @entity788 (VAS 7-8) underwent a subtotal resection of the head of the pancreas with an end-to-side pancreatojejunostomy using a Roux-en-Y loop. @entity158 continued secondary to chronic @entity788 . Because of intolerance ( @entity391 and @entity1142 ) of @entity1286 and transdermal @entity3575 over a 2-month period, it was decided to perform a @entity616 using the anterior approach with ultrasound guidance. The @entity1 's @entity158 was completely relieved, enabling withdrawal of oral analgesics. @entity158 reappeared after 2 years, and the same technique was repeated. Ten days later, she was admitted with @entity6 and @entity360 . Computed tomography showed a left paravertebral @entity733 ; arteriography suggested a @entity292 between the mesenteric vein and the jejunum. Urgent surgery was undertaken, revealing a leak of the pancreatojejunostomy and a large abscess around the celiac plexus. A distal pancreatectomy and partial resection of the Roux-en-Y loop was performed. The @entity1 was discharged 1 month later in good clinical condition. Because of recurrent @entity158 , she has required repeated neurolytic celiac plexus blocks via a posterior approach without complications. CONCLUSION: The posterior approach for @entity616 should be considered in particular in @entity1 with previous pancreatic surgery.

title: @entity733 after XXXX from the anterior approach.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['lower gastrointestinal bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic ketoacidosis']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity733 :: ('MESH:D000038', 'Disease') :: ['retroperitoneal abscess']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

entities_list: @entity616 :: ('MESH:D006327', 'Disease') :: ['neurolytic celiac plexus block']

answer: @entity616 :: (MESH:D006327,Disease) :: ['neurolytic celiac plexus block']


abstract: BACKGROUND: Bony non-unions arising in the aftermath of @entity1161 are commonly managed with vascularized free tissue transfers. Unfortunately, these procedures are invasive and fraught with attendant morbidities. This study investigated a novel, alternative treatment paradigm utilizing adipose-derived stem cells (ASCs) combined with angiogenic @entity5532 ( @entity9268 ) in the @entity35 mandible. METHODS: @entity35 were exposed to a bioequivalent dose of radiation and mandibular osteotomy. Those exhibiting non-unions were subsequently treated with surgical debridement alone or debridement plus combination therapy. Radiographic and biomechanical outcomes were assessed after healing. RESULTS: Significant increases in biomechanical strength and radiographic metrics were observed in response to combination therapy (p < .05). Importantly, combined therapy enabled a 65% reduction in persisting non-unions when compared to debridement alone. CONCLUSION: We support the continued investigation of this promising combination therapy in its potential translation for the management of radiation-induced bony pathology.    2015 Wiley Periodicals, Inc. Head Neck 38: E837-E843, 2016.

title: Translational treatment paradigm for managing non-unions secondary to XXXX utilizing adipose derived stem cells and angiogenic therapy.

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['collateral radiation injury']

entities_list: @entity5532 :: ('MESH:D003676', 'Chemical') :: ['deferoxamine']

answer: @entity1161 :: (MESH:D011832,Disease) :: ['radiation injury']


abstract: AIMS: (1) To assess the 1-year and 6-year courses of non-traumatic knee symptoms in adolescents and young adults presenting in general practice. (2) To identify prognostic factors for persistent knee symptoms at 1-year follow-up. METHODS: Adolescents and young adults (12-35   years; n=172) with non-traumatic knee symptoms were included in the cohort study by their general practitioner (GP) and followed for 6   years. Multivariable logistic regression analysis was used to identify prognostic factors for persistent knee symptoms at 1-year follow-up and the area under the receiver operating curve (AUC) was calculated. RESULTS: Persistent knee symptoms in @entity1 receiving a GP diagnosis of unspecified knee symptoms were reported by 41% of the @entity1 at 1-year follow-up and by 19% of the available @entity1 at 6-year follow-up. @entity1 receiving a GP diagnosis of @entity158 had the worse prognosis, with 40% reporting persistent knee symptoms at 6-year follow-up. Prognostic factors associated with persistent knee symptoms at 1-year follow-up were BMI >25, low/middle education level, bilateral symptoms and self-reported absence of crepitus of the knee (AUC 0.80) for @entity1 receiving a GP diagnosis of unspecified knee symptoms. For @entity1 receiving a GP diagnosis of @entity158 , prognostic factors were low/middle education level, poor health, having bilateral symptoms and self-report of a swollen knee (AUC 0.76). CONCLUSIONS: The prognosis of non-traumatic knee symptoms in adolescents and young adults in general practice is not as good as was previously assumed. Several prognostic factors collected at baseline were associated with persistent knee symptoms at follow-up. However, the results should be replicated in another larger study.

title: The 6-year trajectory of non-traumatic knee symptoms (including XXXX ) in adolescents and young adults in general practice: a study of clinical predictors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['patellofemoral pain syndrome']

answer: @entity158 :: (MESH:D010146,Disease) :: ['patellofemoral pain']


abstract: Dysregulated expression of @entity3823 ( @entity3823 ) is a pathogenetic hallmark of @entity120 . Downregulation of @entity3823 protein but not mRNA has been observed in multiple animal models mimicking the disease, indicating a posttranscriptional mechanism of regulation. Because microRNAs (miRNAs) regulate gene expression mainly through inhibition of target gene translation, we hypothesized that miRNAs may play a role in the modulation of @entity3823 . Performing a computational algorithm on the @entity3823 gene, several miRNAs encoded by the @entity10014 ( @entity66384 ) were retrieved as potential regulators. Ectopic overexpression of @entity66384 resulted in a strong reduction of the @entity3823 protein, and a reporter gene system showed that @entity3823 is directly targeted by @entity12425 and @entity8397 . By stimulation experiments, we found that the @entity66384 cluster is modulated by @entity650 , a cytokine involved in the pathogenesis of @entity120 . Because @entity650 signaling is mainly mediated by @entity4104 ( @entity4104 ), the expression of @entity4104 was knocked down by small interfering RNA, which abolished the @entity650 -mediated expression of @entity66384 . Consistent with these data, we found a highly conserved @entity4104 -binding site in the promoter region of the @entity66384 gene ( @entity10014 ). Promoter studies confirmed that @entity650 enhances transcription of @entity10014 through this distinct region. Finally, we showed that persistent activation of @entity4104 leads to repressed protein expression of @entity3823 . Taken together, we describe here a novel @entity4104 - @entity66384 - @entity3823 pathway, thus providing a mechanistic explanation for the loss of @entity3823 in the development of @entity120 .

title: @entity650 modulates the expression of the bone morphogenic protein receptor type II through a novel XXXX -microRNA cluster 17/92 pathway.

entities_list: @entity3823 :: ('659', 'Gene') :: ['BMPR2', 'bone morphogenetic protein receptor type II']

entities_list: @entity4104 :: ('6774', 'Gene') :: ['STAT3', 'signal transducer and activator of transcription 3']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

answer: @entity4104 :: (6774,Gene) :: ['STAT3']


abstract: UNASSIGNED: Abnormalities in the levels of @entity460 , @entity3151 , and @entity461 ( @entity461 ) in serum are typical for @entity1 with @entity740 ( @entity740 ). They are used routinely to predict the onset of @entity79 ( @entity740 ). However, @entity740 associated with metabolic pathway imbalance is not well understood.The objective of the study was to identify endogenous metabolic signatures in @entity1 with intact @entity461 using mass spectrometry-based metabolomics. This study was a cross-sectional study. Ultra performance liquid chromatography-Quadrupole Time-of-Flight/mass spectrometry-based metabolic profiling was employed to analyze serum samples from 19 disease controls (DCs) (intact @entity461 [iPTH] 150-300pg/mL) and 19 @entity3528 ( @entity3528 ) @entity1 (iPTH >300pg/mL) (the training data set) to identify metabolic biomarkers for @entity740 . Then, another set of samples including 19 DCs (iPTH 150-300pg/mL) and 19 @entity3528 @entity1 (iPTH >300pg/mL) (the test data set) were used to validate the potential biomarkers identified.Metabolic profiling analyses revealed different patterns of endogenous metabolites between the @entity3528 and the DC groups. A total of 32 unique metabolites were identified and 30 metabolites were elevated in the iPTH compared with control serum pools. @entity3183 and @entity10841 were downregulated in the @entity3528 @entity1 . The metabolic signatures identified were assessed respectively by an internal 10-fold cross validation with an accuracy of 91.4% and an external validation with an accuracy of 71.1%, a sensitivity of 73.7%, and a specificity of 68.4%.Mass spectrometry-based metabolomic analyses for @entity3528 @entity1 promises immense potential for early diagnosis and therapy monitoring. Our results indicated that the onset of @entity740 is associated with pathway changes of protein synthesis and metabolism, @entity3689 metabolism, energy metabolism, and @entity479 hormone metabolism, with obvious promise for better understanding the pathogenesis of this disease. Several metabolic biomarkers were identified, which warrant further development.

title: Evidence for XXXX Associated With Metabolic Pathway Changes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary hyperparathyroidism', 'SHPT']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'CKD-MBD', 'chronic kidney disease', 'MBD']

entities_list: @entity10841 :: ('CHEBI:58095', 'Chemical') :: ['L-phenylalanine']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['CKD-mineral and bone disorder']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3183 :: ('MESH:D003562', 'Chemical') :: ['Cytidine']

entities_list: @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']

entities_list: @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone']

answer: @entity740 :: (MESH:D051436,Disease) :: ['Chronic Kidney Disease-Mineral and Bone Disorder']


abstract: OBJECTIVES: To report the clinical features of @entity4858 associated with explosive military ammunition in insurgent attacks in @entity233 . METHODS: The medical records of 48 casualties who were treated for @entity4858 sustained in insurgent attacks at the Combat Region Hospitals in @entity233 were retrospectively reviewed. The reviewed data included initial visual acuity, type of explosive military ammunition (ie, improvised explosive device, mine, hand grenade and rocket-propelled grenade), @entity130 ( @entity1538 vs @entity130 ), traumatised globe zones, the presence/absence of an intraocular foreign body, medical interventions, status during the explosion and @entity130 to other parts of the body. The visual acuity differences between different explosive materials and between 'on-foot' and 'inside-vehicle' casualties were investigated. RESULTS: A total of 83 injured eyes were analysed. The mean @entity1 age was 24.5  6.6   years. The mean initial logarithm of the minimum angle of resolution visual acuity was 0.60  0.63. The @entity130 were due to improvised explosive devices in 28 cases (58.3%), land mines in 16 cases (33.3%), and hand grenades and rocket-propelled grenades in 2 cases each (4.2%). Forty-seven eyes (56.6%) had @entity542 . The most frequently involved zones were zone 1 (50.0%) in closed-globe @entity130 and all zones (31.9%) in @entity542 . Intraocular foreign bodies were present in 45/47 (95.7%) eyes with @entity542 . Twelve (14.4%) eyes with no light perception were enucleated, and two (2.4%) eviscerated. The difference in the visual acuities between the on-foot and inside-vehicle casualties and between the @entity130 that were caused by the different types of explosive ammunitions was also insignificant (p=0.271 and 0.394, respectively). CONCLUSIONS: The clinical results for @entity4858 caused by explosive military ammunition sustained during insurgent attacks in @entity233 are disappointing irrespective of the explosive material. The use of protective eyeglasses might improve the outcomes and should be encouraged.

title: XXXX related to explosive military ammunition.

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['open-globe injuries']

entities_list: @entity4858 :: ('MESH:D005131', 'Disease') :: ['eye injuries', 'ocular injuries']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['closed-globe injury', 'type of globe injury', 'injuries']

answer: @entity4858 :: (MESH:D005131,Disease) :: ['Ocular blast injuries']


abstract: PURPOSE: To characterize the expression profile of @entity9486 in @entity1 normal tissues by immunohistochemistry (IHC) and to analyze the correlation between @entity9486 expression and @entity150 progression. EXPERIMENTAL DESIGN: CJDp73 was characterized for p73alpha detection in Western blot and IHC through its application to isoform-transfected 293 cells. Normal tissues were analyzed by IHC with the CJDp73 antiserum. @entity1606 ( @entity1606 )-derived cell lines were subjected to reverse transcription-PCR and Western blot. @entity1606 tissue microarrays were analyzed for p73alpha expression by IHC, and the results were statistically analyzed. RESULTS: @entity9486 immunostaining was nuclear and restricted to epithelial cells of certain organs such as squamous epithelium of the epidermis and transitional epithelium of the bladder. The expression was also observed in certain specialized glandular epithelia such as acinar cells of breast and parotid gland. Four of seven @entity1606 -derived cell lines had low to undetectable p73alpha protein levels. We found undetectable or low p73alpha expression in 104 of 154 (68%) @entity1606 cases, this phenotype being more frequently observed in invasive @entity5 when compared with superficial lesions. This association was statistically significant (P < 0.0001). We also observed a significant association between @entity876 , @entity4206 , and p73alpha alterations with @entity150 progression (P < 0.0001). CONCLUSIONS: p73alpha plays a @entity5 suppressor role in @entity150 , and its inactivation occurs through an epigenetic mechanism, most probably involving protein degradation.

title: @entity9486 Expression in @entity1 normal and @entity5 tissues: loss of p73alpha expression is associated with XXXX progression in @entity150 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

entities_list: @entity1606 :: ('MESH:D002295', 'Disease') :: ['Transitional cell carcinoma', 'TCC']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: UNASSIGNED: Compression therapy is the basis for successful treatment in most @entity1 with @entity3179 . Concerning compression therapy, the initial phase of decongestion and the following phase of maintenance should be differentiated. While in the maintenance phase (ulcer) stocking systems are now frequently recommended, in the decongestion phase compression bandages are mostly still used, which however are often inappropriately applied. In German-speaking countries, compression therapy with short-stretch bandages has a  long tradition. However, their correct application requires good training and monitoring, which is often lacking in daily practice. @entity34 are multicomponent systems, some of which have an optical marker for the control of the correct subbandage pressure. In another new type of compression system, which is called adaptive or wrap bandages, the compression pressure can be adjusted using a Velcro fastener. Accompanying intermittent pneumatic compression therapy can also be used in the decongestion phase. Thus, there are now several different treatment options that can be used for the decongestion phase in @entity1 with @entity3179 . Often bandages with short-stretch materials are very prone to errors and should in most cases be replaced by other compression systems today. The @entity1 's preference, need, and capability should be considered when selecting the appropriate system for the individual @entity1 .

title: [Compression therapy of XXXX in the decongestion phase].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3179 :: ('MESH:D014647', 'Disease') :: ['venous leg ulcers']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['Less error-prone treatment alternatives']

answer: @entity3179 :: (MESH:D014647,Disease) :: ['venous leg ulcers']


abstract: OBJECTIVE: Use of @entity9213 as a selective @entity2247 inhibitor for treatment of adult @entity627 decreases the frequency of gastrointestinal (GI) side effects in comparison with nonselective COX inhibitors. Up to 50% of @entity1 with @entity309 ( @entity309 ) also develop GI side effects through nonselective COX inhibitors. In this 12 week Phase I/II study, with an additional open extension lasting up to 52 weeks, the safety, efficacy, and pharmacokinetics of @entity9213 in @entity309 were investigated. METHODS: @entity9213 suspension 0.25 mg/kg once daily was given to 36 @entity1 with @entity309 who required a nonsteroidal antiinflammatory drug. Safety evaluation and periodic measurement of efficacy were carried out using the Pediatric Rheumatology International Trials Organisation (PRINTO) criteria. Eighteen @entity1 underwent pharmacokinetic (PK) evaluation. RESULTS: Thirty-one @entity1 completed the study. Four were dropped due to administrative reasons. One @entity1 , who found the drug ineffective, discontinued participation. A response was seen according to PRINTO outcome criteria in 44% of the @entity1 at Week 4, 62% at Week 12, and 74% at Week 52. Drug related adverse events were observed in 5 @entity1 . PK evaluation showed that the maximum plasma concentration Cmax of -34% and AUC(0-infinity) of -28% tended to be lower in younger @entity1 (2-6 years) versus older @entity1 . Plasma elimination half-life (13 h) was similar in all @entity1 . CONCLUSION: @entity9213 suspension 0.25 mg/kg once daily seems to be effective and safe for treating active @entity309 over a period of 52 weeks.

title: High response rate in the phase I/II study of @entity9213 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic diseases']

entities_list: @entity9213 :: ('MESH:C065757', 'Chemical') :: ['meloxicam', 'Meloxicam']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['juvenile rheumatoid arthritis', 'JRA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['juvenile rheumatoid arthritis']